Home
Search
Search Results
Previously Searched
3018 results found
Expand All
Apply All
3018 results found

2016 BIO CEO & Investor Conference Buzz of BIO Winners Announced
Press Release  •  January 12, 2016
Recognizing highly innovative companies in the biotech sector
Read More

BIO Announces Appointment of Dan Durham to Lead Health Policy Section
Press Release  •  January 7, 2016
BIO announced today that long-time healthcare policy expert Dan Durham will be joining BIO as Executive Vice President and will lead the organization’s Health Policy Section.
Read More

Biotechnology Industry Organization changes name to Biotechnology Innovation Organization
Press Release  •  January 4, 2016
New Name Better Reflects Member's Innovations and Breakthroughs; Organization Will Still Use BIO Name
Read More

Congressional Black Caucus Letter to EPA on RFS RVO
Agriculture & Environment, Sustainable Fuels, Renewable Fuel Standard (RFS)  •  Letters, Testimony & Comments  •  October 30, 2015
As you finalize the proposed rules under the Renewable Fuel Standard, we respectfully urge you to not reduce the biofuels volume requirements. The RFS program has helped the environment, our economy, and has increased our confidence in renewable fuels. Renewable fuels like cellulosic and advanced biofuels have reduced greenhouse gas and carbon emissions to an equivalent of removing more than 124 million cars from the roads. 
Read More

BIO Submits Comments Re: FDA Rare Diseases Guidance
Rare Diseases  •  Letters, Testimony & Comments  •  October 22, 2015
RE: Docket No. FDA–2015–D–2818 Draft Guidance for Industry: Rare Diseases—Common Issues in Drug Development Dear Sir/Madam: The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide feedback in response to the Food and Drug Administration’s (FDA’s) Draft Guidance for Industry, entitled “Rare Diseases: Common Issues in Drug Development” (Draft Guidance). BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial, and environmental biotechnology products.
Read More

Rare Diseases: BIO Comments on Complex Issues for Rare Diseases
Rare Diseases  •  Letters, Testimony & Comments  •  March 10, 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments to the docket regarding “Complex Issues in Developing Drug and Biologics Products for Rare Diseases.” Comments are being provided in two areas; general comments on the challenges of rare disease drug development, and specific comments in response to the public workshop.
Read More

FDA, Rare Diseases, Orphan Drug Act: Food and Drug Administration Review and Regulation of Articles for the Treatment of Rare Diseases
Rare Diseases  •  Letters, Testimony & Comments  •  May 31, 2010
BIO’s final comments on Considerations Regarding Food and Drug Administration Review and Regulation of Articles for the Treatment of Rare Diseases.
Read More

Statement Regarding Interactions With Healthcare Professionals
Press Release  •  February 19, 2009
Statement regarding Interactions with Healthcare ProfessionalsBIO and our member companies remain dedicated to the improvement of patient care and the advancement of medical science.  In pursuing this mission, we recognize that adherence to strict ethical standards and compliance with applicable laws is critical to our industry’s ability to continue our collaboration with healthcare professionals and maintain the trust of our patients.  For these reasons, BIO supports the principles in PhRMA’s Code governing interactions with healthcare professionals, and will continue to encourage its members to maintain the highest standards for ethical business practices and socially responsible industry conduct related to company interactions with healthcare professionals.Specifically, BIO encourages each of its member companies that are involved in the marketing of biologics or other pharmaceuticals to United States healthcare professionals to adopt a transparent and rigorous code of conduct, such as the PhRMA Code, tailored as appropriate to its own particular circumstances and which also ensures compliance with all applicable local, state, and federal laws and regulations.  BIO members that wish to sign on to the PhRMA Code may do so, even if they are not PhRMA members. 
Read More